Departments of Pediatrics and of Human Genetics, University of Michigan, Ann Arbor, MI 48109-5446, USA.
Hum Genet. 2011 Jan;129(1):79-90. doi: 10.1007/s00439-010-0902-8. Epub 2010 Oct 30.
Bardet-Biedl syndrome (BBS) is a rare, primarily autosomal-recessive ciliopathy. The phenotype of this pleiotropic disease includes retinitis pigmentosa, postaxial polydactyly, truncal obesity, learning disabilities, hypogonadism and renal anomalies, among others. To date, mutations in 15 genes (BBS1-BBS14, SDCCAG8) have been described to cause BBS. The broad genetic locus heterogeneity renders mutation screening time-consuming and expensive. We applied a strategy of DNA pooling and subsequent massively parallel resequencing (MPR) to screen individuals affected with BBS from 105 families for mutations in 12 known BBS genes. DNA was pooled in 5 pools of 21 individuals each. All 132 coding exons of BBS1-BBS12 were amplified by conventional PCR. Subsequent MPR was performed on an Illumina Genome Analyzer II™ platform. Following mutation identification, the mutation carrier was assigned by CEL I endonuclease heteroduplex screening and confirmed by Sanger sequencing. In 29 out of 105 individuals (28%), both mutated alleles were identified in 10 different BBS genes. A total of 35 different disease-causing mutations were confirmed, of which 18 mutations were novel. In 12 additional families, a total of 12 different single heterozygous changes of uncertain pathogenicity were found. Thus, DNA pooling combined with MPR offers a valuable strategy for mutation analysis of large patient cohorts, especially in genetically heterogeneous diseases such as BBS.
Bardet-Biedl 综合征(BBS)是一种罕见的、主要为常染色体隐性遗传的纤毛病。这种多效性疾病的表型包括视网膜色素变性、轴后多指(趾)、躯干肥胖、学习障碍、性腺功能减退和肾脏异常等。迄今为止,已有 15 个基因(BBS1-BBS14、SDCCAG8)的突变被描述为导致 BBS。广泛的遗传基因座异质性使得突变筛查既耗时又昂贵。我们应用 DNA 池化和随后的大规模平行重测序(MPR)策略,对来自 105 个家庭的受 BBS 影响的个体进行 12 个已知 BBS 基因的突变筛查。DNA 被分成 5 个 21 人一组的池。通过常规 PCR 扩增 BBS1-BBS12 的所有 132 个编码外显子。随后在 Illumina Genome Analyzer II™平台上进行 MPR。在确定突变后,通过 CEL I 内切酶异源双链体筛选分配突变携带者,并通过 Sanger 测序进行确认。在 105 个个体中的 29 个(28%)中,在 10 个不同的 BBS 基因中发现了两个突变等位基因。总共确认了 35 个不同的致病突变,其中 18 个是新的。在另外 12 个家庭中,总共发现了 12 个不同的、不确定致病性的单杂合变化。因此,DNA 池化结合 MPR 为大患者队列的突变分析提供了一种有价值的策略,特别是在遗传异质性疾病如 BBS 中。